Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5269 - Survival Gains from Advances in First-Line Systemic Therapy for HER2-Positive Metastatic Breast Cancer in the U.S., 1995-2015


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Joshua Roth


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


J. Roth1, P. Bajaj2, S. Sullivan3, C. Reyes4, V. Antao5, A. Stein6, R. Mahtani7, S. Ramsey8

Author affiliations

  • 1 Public Health Sciences, Fred Hutchinson Cancer Research Center, 98109 - Seattle/US
  • 2 Health Economics And Outcomes Research, Genentech Inc. - Roche - USA, 94080 - South San Francisco/US
  • 3 Pharmacy, University of Washington, Seattle/US
  • 4 Health Economics And Outcomes Research, Genentech Inc., 94080 - South San Francisco/US
  • 5 Us Medical Affairs, Genentech Inc. - Roche - USA, 94080 - South San Francisco/US
  • 6 Breast & Gyn Oncology, Genentech Inc., 94080 - South San Francisco/US
  • 7 Hematology/oncology, Sylvester Comprehensive Cancer Center, Deerfield Beach/US
  • 8 Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle/US


Abstract 5269


Of the approximately 67,000 women diagnosed with metastatic breast cancer (mBC) annually in the U.S., nearly 10,700 are HER2-positive (HER2+). Prior to the advent of HER2 targeted therapy, women with HER2+ mBC had a less favorable prognosis than those with HER2-negative mBC. The objective of this study was to quantify survival gains for women with HER2+ mBC from 1995-2015, a period spanning pre HER2 targeted therapy to the present, where multiple targeted therapies are available.


We developed a simulation model to estimate overall survival (OS) for successive cohorts diagnosed with HER2+ mBC from 1995-2015. OS data were derived from clinical trials referenced in NCCN guidelines and extrapolated to a lifetime horizon by fitting Weibull curves. Patients were assigned to regimens in each diagnosis year using information from the IPSOS ‘Global Oncology Monitor’- a commercial treatment registry. Results were calibrated with SEER OS data. Outcomes included 5-year OS, expected OS, and total life years (LYs) for all patients with HER2+ mBC. Annual incidence of HER2+ mBC was assumed to be constant over time.


Over the period 1995-2015, expected 5-year OS for women with HER2+ mBC increased by 28.9%. Mean expected per-patient OS improved by 28.1 months (25,000 population LYs) (see Table). The largest gain (15.7 months) occurred between 2010 and 2015–the period over which pertuzumab-based treatment was approved for first-line use and gained substantial market penetration. The smallest gain (2.4 months) occurred between 1995 and 2000—the period over which trastuzumab-based treatment was approved, but had not yet achieved market penetration.


The introduction and expanded use of targeted treatments, along with other advances in care, have provided substantial individual- and population-level survival gains for women with HER2+ mBC. A considerable proportion of the expected OS differences between 1995 and 2015 took place after the introduction and uptake of trastuzumab and pertuzumab-based regimens.Table:


Diagnosis Year5-Year OS (%)Mean Per-Patient OS (Months)Population Life Years

Clinical trial identification

Not applicable

Legal entity responsible for the study





J. Roth, S. Sullivan, S. Ramsey: Research funding from Genentech, Inc. P. Bajaj, C. Reyes, V. Antao, A. Stein: Employee of Genentech, Inc; Stock Ownership in Roche. R. Mahtani: Advisory boards for Genentech, Pfizer, Amgen, Celgene, Sandoz; Research support from Genentech.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.